Jin, Yinzhu
Landon, Joan E.
Krueger, Whitney
Liede, Alexander
Desai, Rishi J.
Kim, Seoyoung C. http://orcid.org/0000-0002-2517-3579
Funding for this research was provided by:
AbbVie Biotherapeutics (2018A018586)
Article History
Accepted: 12 June 2022
First Online: 30 June 2022
Declarations
:
: This project was supported by AbbVie (grant number: 2018A018586).
: The sponsor provided the data access to the authors at Brigham and Women’s Hospital via the third-party agreement. The authors at Brigham and Women’s Hospital analyzed the data, interpreted the results, determined the final wording of the manuscript, and had the final decision to submit the manuscript for publication. The sponsor was given the opportunity to make nonbinding comments on a draft of the manuscript. Publication of this article was not contingent upon approval by the sponsor.
: Jin and Landon declare that they have no conflict of interest. Desai reports receiving research grants from Bayer, Vertex, and Novartis for unrelated research. Liede and Krueger are full-time AbbVie employees and therefore own AbbVie stock. Kim has received research grants to the Brigham and Women’s Hospital from Pfizer, AbbVie, Roche and Bristol-Myers Squibb.
: The data that support the findings of this study are not publicly available.
: The codes that support the findings of this study are available from the corresponding author, SCK, upon reasonable request.
: All authors meet the journal’s criteria for authorship. All authors have contributed to the work and approve the presented findings.
: The study protocol was reviewed and approved by the Institutional Review Board (IRB) of the Brigham and Women’s Hospital (IRB protocol number: 2019P003604).
: Patient-informed consent was not required, since the data were deidentified.
: Not applicable.